PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression

Cancer statistics, 2022

(2022) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis

(2022) Linjun Shi et al.   MOLECULAR THERAPY

HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer

(2022) Yingke Zhou et al.   Theranostics

Cancer Immunoediting in the Era of Immuno-oncology

(2022) Matthew M. Gubin et al.   CLINICAL CANCER RESEARCH

The “Inside” Story on Tumor-Expressed PD-L1

(2022) Brent A. Hanks   CANCER RESEARCH

Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IκBα

(2022) Dong Guo et al.   Cell Metabolism

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

(2022) A. Psyrri et al.   ANNALS OF ONCOLOGY

A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC

(2022) Laurel B. Darragh et al.   Nature Cancer

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Circadian clock: a regulator of the immunity in cancer

(2021) Zhen Zhang et al.   Cell Communication and Signaling

The role of the circadian clock in cancer hallmark acquisition and immune-based cancer therapeutics

(2021) Elizabeth Cash et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Lactate secreted by PKM2 upregulation promotes Galectin-9-mediated immunosuppression via inhibiting NF-κB pathway in HNSCC

(2021) Hanyue Chang et al.   Cell Death & Disease

Advancing to the era of cancer immunotherapy

(2021) Yun Wang et al.   Cancer Communications

Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial

(2021) Joël Guigay et al.   Journal for ImmunoTherapy of Cancer

Neoadjuvant checkpoint blockade for cancer immunotherapy

(2020) Suzanne L. Topalian et al.   SCIENCE

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

(2020) R.L. Ferris et al.   ANNALS OF ONCOLOGY

Treatment after progression in the era of immunotherapy

(2020) Salem Billan et al.   LANCET ONCOLOGY

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression

(2019) Xiangfeng Shen et al.   Frontiers in Immunology

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

(2019) Ezra E. W. Cohen et al.   Journal for ImmunoTherapy of Cancer

PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition

(2019) Yilun Wu et al.   Frontiers in Immunology

Downregulation of the circadian Period family genes is positively correlated with poor head and neck squamous cell carcinoma prognosis

(2019) Yuan-yuan Li et al.   CHRONOBIOLOGY INTERNATIONAL

Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma

(2019) Valerie Cristina et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Mechanisms Controlling PD-L1 Expression in Cancer

(2019) Jong-Ho Cha et al.   MOLECULAR CELL

Cyclin-dependent kinase 5 (CDK5) regulates the circadian clock

(2019) Andrea Brenna et al.   eLife

Pan-Cancer Analysis Reveals Disrupted Circadian Clock Associates With T Cell Exhaustion

(2019) Yingcheng Wu et al.   Frontiers in Immunology

Escaping Circadian Regulation: An Emerging Hallmark of Cancer?

(2018) Rukeia El-Athman et al.   Cell Systems

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Hallmarks of Cancer-Related Newly Prognostic Factors of Oral Squamous Cell Carcinoma

(2018) Tomonori Sasahira et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The Circadian Protein Period2 Suppresses mTORC1 Activity via Recruiting Tsc1 to mTORC1 Complex

(2018) Rong Wu et al.   Cell Metabolism

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy

(2018) Dan P. Zandberg et al.   EUROPEAN JOURNAL OF CANCER

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC

(2018) Lillian L. Siu et al.   JAMA Oncology

The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint

(2017) Qingshui Wang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells

(2017) Hiro Sato et al.   Nature Communications

Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives

(2017) Xiongwen Ran et al.   Drug Design Development and Therapy

Deubiquitination and Stabilization of PD-L1 by CSN5

(2016) Seung-Oe Lim et al.   CANCER CELL

Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants

(2016) Subrata Chowdhury et al.   Oncotarget

Oral cavity and oropharyngeal squamous cell carcinoma-an update

(2015) Angela C. Chi et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Circadian variations of clock gene Per2 and cell cycle genes in different stages of carcinogenesis in golden hamster buccal mucosa

(2015) Xue-Mei Tan et al.   Scientific Reports

Circadian Timing in Cancer Treatments

(2010) Francis Lévi et al.   Annual Review of Pharmacology and Toxicology